company background image
2186 logo

Luye Pharma Group SEHK:2186 Stock Report

Last Price

HK$3.82

Market Cap

HK$14.4b

7D

35.9%

1Y

30.8%

Updated

12 Jun, 2025

Data

Company Financials +

Luye Pharma Group (2186) Stock Overview

Develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally. More details

2186 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth4/6
Past Performance1/6
Financial Health4/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for 2186 from our risk checks.

2186 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Luye Pharma Group Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Luye Pharma Group
Historical stock prices
Current Share PriceHK$3.82
52 Week HighHK$3.92
52 Week LowHK$1.67
Beta0.80
1 Month Change94.90%
3 Month Change60.50%
1 Year Change30.82%
3 Year Change59.17%
5 Year Change-26.40%
Change since IPO-42.99%

Recent News & Updates

It's Probably Less Likely That Luye Pharma Group Ltd.'s (HKG:2186) CEO Will See A Huge Pay Rise This Year

May 21
It's Probably Less Likely That Luye Pharma Group Ltd.'s (HKG:2186) CEO Will See A Huge Pay Rise This Year

Recent updates

It's Probably Less Likely That Luye Pharma Group Ltd.'s (HKG:2186) CEO Will See A Huge Pay Rise This Year

May 21
It's Probably Less Likely That Luye Pharma Group Ltd.'s (HKG:2186) CEO Will See A Huge Pay Rise This Year

Investors Appear Satisfied With Luye Pharma Group Ltd.'s (HKG:2186) Prospects

Feb 11
Investors Appear Satisfied With Luye Pharma Group Ltd.'s (HKG:2186) Prospects

Here's Why Luye Pharma Group (HKG:2186) Has A Meaningful Debt Burden

Dec 22
Here's Why Luye Pharma Group (HKG:2186) Has A Meaningful Debt Burden

Unpleasant Surprises Could Be In Store For Luye Pharma Group Ltd.'s (HKG:2186) Shares

Sep 25
Unpleasant Surprises Could Be In Store For Luye Pharma Group Ltd.'s (HKG:2186) Shares

Does Luye Pharma Group (HKG:2186) Have A Healthy Balance Sheet?

Aug 29
Does Luye Pharma Group (HKG:2186) Have A Healthy Balance Sheet?

Luye Pharma Group Ltd.'s (HKG:2186) Earnings Haven't Escaped The Attention Of Investors

Jun 19
Luye Pharma Group Ltd.'s (HKG:2186) Earnings Haven't Escaped The Attention Of Investors

We Discuss Why Luye Pharma Group Ltd.'s (HKG:2186) CEO Compensation May Be Closely Reviewed

May 21
We Discuss Why Luye Pharma Group Ltd.'s (HKG:2186) CEO Compensation May Be Closely Reviewed

Here's Why Luye Pharma Group (HKG:2186) Has A Meaningful Debt Burden

Apr 26
Here's Why Luye Pharma Group (HKG:2186) Has A Meaningful Debt Burden

Is Luye Pharma Group Ltd. (HKG:2186) Trading At A 27% Discount?

Feb 29
Is Luye Pharma Group Ltd. (HKG:2186) Trading At A 27% Discount?

Some Confidence Is Lacking In Luye Pharma Group Ltd.'s (HKG:2186) P/S

Jan 09
Some Confidence Is Lacking In Luye Pharma Group Ltd.'s (HKG:2186) P/S

Luye Pharma Group (HKG:2186) Takes On Some Risk With Its Use Of Debt

Dec 19
Luye Pharma Group (HKG:2186) Takes On Some Risk With Its Use Of Debt

A Look At The Fair Value Of Luye Pharma Group Ltd. (HKG:2186)

Nov 24
A Look At The Fair Value Of Luye Pharma Group Ltd. (HKG:2186)

Is Luye Pharma Group (HKG:2186) A Risky Investment?

Sep 12
Is Luye Pharma Group (HKG:2186) A Risky Investment?

Luye Pharma Group Ltd.'s (HKG:2186) Intrinsic Value Is Potentially 20% Below Its Share Price

Aug 17
Luye Pharma Group Ltd.'s (HKG:2186) Intrinsic Value Is Potentially 20% Below Its Share Price

Is Luye Pharma Group (HKG:2186) Using Too Much Debt?

May 10
Is Luye Pharma Group (HKG:2186) Using Too Much Debt?

We Think Luye Pharma Group (HKG:2186) Is Taking Some Risk With Its Debt

Sep 20
We Think Luye Pharma Group (HKG:2186) Is Taking Some Risk With Its Debt

Shareholder Returns

2186HK PharmaceuticalsHK Market
7D35.9%5.0%3.1%
1Y30.8%43.7%26.3%

Return vs Industry: 2186 underperformed the Hong Kong Pharmaceuticals industry which returned 43.7% over the past year.

Return vs Market: 2186 exceeded the Hong Kong Market which returned 26.3% over the past year.

Price Volatility

Is 2186's price volatile compared to industry and market?
2186 volatility
2186 Average Weekly Movement9.2%
Pharmaceuticals Industry Average Movement7.8%
Market Average Movement7.8%
10% most volatile stocks in HK Market14.9%
10% least volatile stocks in HK Market4.2%

Stable Share Price: 2186 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 2186's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19945,150Dian Bo Liuwww.luye.cn

Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; and Seroquel, Seroquel XR, Erzofri, Rivastigmine Multi-Day Transdermal Patch, and Rivastigmine.

Luye Pharma Group Ltd. Fundamentals Summary

How do Luye Pharma Group's earnings and revenue compare to its market cap?
2186 fundamental statistics
Market capHK$14.37b
Earnings (TTM)HK$516.09m
Revenue (TTM)HK$6.63b
27.8x
P/E Ratio
2.2x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2186 income statement (TTM)
RevenueCN¥6.06b
Cost of RevenueCN¥2.02b
Gross ProfitCN¥4.04b
Other ExpensesCN¥3.57b
EarningsCN¥471.89m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.13
Gross Margin66.72%
Net Profit Margin7.79%
Debt/Equity Ratio65.1%

How did 2186 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/12 21:12
End of Day Share Price 2025/06/12 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Luye Pharma Group Ltd. is covered by 19 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ling ZhangBNP Paribas Securities (Asia)
Jessica LiBofA Global Research
Lok Kwan ChiuCCB International Securities Limited